IRulya Therapeutics Inc. Common Stock
IRLA
37 hedge funds and large institutions have $104M invested in IRulya Therapeutics Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
9.17% more ownership
Funds ownership: 0% → 9.17% (+9.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SUT
SC US (TTGP)
Menlo Park,
California
|
+$31.1M |
| 2 |
Alphabet Inc
Mountain View,
California
|
+$13.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.22M |
| 4 |
BlackRock
New York
|
+$4.16M |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$2.99M |
Top Sellers
IRLA Hedge Fund Activity: Q2 2019 in Review
37 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q2 2019, worth a combined $104M.
Buyers outnumbered sellers: 37 funds opened new IRLA positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was SC US (TTGP), opening a new position worth an estimated $31.1M.
- 37 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $104M of IRulya Therapeutics Inc. Common Stock stock for Q2 2019.
- 37 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +37 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q2 2019 was SC US (TTGP), an estimated $31.1M added.
Based on aggregated 13F filings for Q2 2019.